Print

BrainStorm Cell Therapeutics Inc. Receives Grant from Israel’s Office of the Chief Scientist  
9/26/2011 10:36:17 AM

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell therapeutics targeting Central Nervous System (CNS) diseases, today announced that it received notice from Israel’s Office of the Chief Scientist (OCS) of its commitment to grant the Company approximately $1.1 million (NIS 3.8 million) in accordance with OCS requirements.
//-->